Fennec Pharmaceuticals (TSE:FRX) Stock Passes Above 50 Day Moving Average - Should You Sell?

Key Points

• Fennec Pharmaceuticals Inc. shares surpassed their 50-day moving average, trading at C$12.78, which indicates positive momentum in the stock's performance.
• The company has a market capitalization of C$355.69 million and significant liquidity with a current ratio of 7.80 and a quick ratio of 10.17.
• Insider activity shows that Director Rostislav Christov Raykov sold 10,000 shares at an average price of C$11.71, raising a total of C$117,096 in July.

Fennec Pharmaceuticals Inc. (TSE:FRX - ) shares passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$11.87 and traded as high as C$12.78. Fennec Pharmaceuticals shares last traded at C$12.78, with a volume of 100 shares changing hands.

Fennec Pharmaceuticals Stock Performance

The company has a 50 day moving average price of C$11.87 and a 200-day moving average price of C$10.29. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The company has a market cap of C$355.69 million, a P/E ratio of -28.40 and a beta of 2.09.

Insider Activity

In other news, Director Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction on Thursday, July 3rd. The stock was sold at an average price of C$11.71, for a total value of C$117,096.00. In the last 90 days, insiders sold 13,246 shares of company stock valued at $137,297. Company insiders own 16.20% of the company's stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.